USA The American pharmaceutical market dominates the global landscape, accounting for nearly 50 percent of all global prescription drug sales by value. In 2024, the US market alone generated roughly USD 800 billion of the USD 1.7 trillion worldwide pharmaceutical revenue, cementing its status as the undisputed epicentre of the global…
Puerto Rico Puerto Rico is a secure US platform from which global life sciences companies can innovate, scale, and strengthen their global competitiveness. Ella Woger-Nieves, CEO of Invest Puerto Rico, discusses the island’s evolving position as a life sciences hub and how global supply chain reconfigurations are driving a new wave of…
Puerto Rico When evaluating your strategic investment or site selection, look to Puerto Rico, bring us your requirements, and give us the opportunity to build the business case together. Carlos J. Ríos Pierluisi, Secretary of the Department of Economic Development and Commerce (DEDC) of Puerto Rico, discusses the island’s strategic position as…
USA A runthrough of the most impactful trends for the pharmaceutical industry in the US, part of our upcoming Healthcare & Life Sciences Review on the USA. MFN & Onshoring Deals: The Price of Avoiding 100% Tariffs US tariffs, or the threat of them, are having a huge impact on…
Hong Kong Hong Kong recently announced its first-ever Five-Year Plan, the latest sign of closer alignment with mainland China. With a clearer roadmap to 2030, what are the implications for biopharma? A First FYP Even since returning to Chinese control in 1997, Hong Kong has maintained its role as a trading…
Spain With a huge investment from AstraZeneca at its core, can the Spanish city of Barcelona really now rival more established European life sciences ecosystems? Back in 2023, Barcelona was a somewhat surprising choice for AstraZeneca’s new global R&D hub. The Catalan capital, Spain’s second largest city, lacks both the…
Europe ESTEVE has successfully reshaped itself in the recent years as an integrated healthcare company with two distinct growth engines: highly specialised pharmaceuticals and a global small-molecule CDMO platform, united by a shared purpose, long-term vision and a commitment to improving patients’ lives. As the US grows in relevance and investment…
Germany At its core, we need a reform of the welfare state. It’s indispensable, but it needs to be brought back to its core purpose: help for those who need it – not excessive transfer payments Klaus Holetschek served as Bavarian Health Minister during the pandemic and now chairs the CSU…
USA Thomas Seewoester, Vice President Site Operations and Site Head at Amgen Manufacturing Limited, LLC, has overseen Puerto Rico’s most significant manufacturing campus for three years, building on more than three decades of Amgen presence and USD six billion in cumulative investment. Seewoester discusses the rationale behind a further USD one…
Korea We are actively evolving into a nation that discovers innovative drug candidates Korea’s clinical trial sector has spent the past two decades transforming itself from a fast follower into one of the industry’s most closely watched growth stories. Hyejin Kim, Chairperson of KoNECT, has been at the centre of that…
Germany Establishing a genuine European investment promotion platform is crucial Achim Hartig, Director of Foreign Direct Investment at Germany Trade & Invest (GTAI) and Chair of the OECD Network of Investment Promotion Agencies, discusses Germany’s evolving investment priorities, spanning healthcare, energy, digital technologies and mobility. He highlights the country’s strengths in…
Germany Dr Gertrud Demmler of SBK, one of Germany’s largest statutory health insurance funds, describe the EUR 18 billion funding gap facing the country’s health system, what the July 2026 GKV Contribution Rate Stabilisation Act does and doesn’t fix, why consolidation among health insurance funds is set to continue, and the…
See our Cookie Privacy Policy Here